Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 237

1.

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.

Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152-0. doi: 10.1016/j.ygyno.2019.03.004. [Epub ahead of print]

PMID:
30876674
2.

Application of Adeno-Associated Virus Vectors for Engineering SCF-Containing Extracellular Vesicles of Mesenchymal Stromal Cells.

Zubkova ES, Beloglazova IB, Evtushenko EG, Kopylov AT, Shevchenko EK, Dergilev KV, Ratner EI, Parfenova EV, Men'shikov MY.

Bull Exp Biol Med. 2019 Feb;166(4):527-534. doi: 10.1007/s10517-019-04387-2. Epub 2019 Feb 22.

PMID:
30793234
3.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7.

PMID:
30630630
4.

Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes.

Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Obstet Invest. 2019 Jan 2:1-8. doi: 10.1159/000493132. [Epub ahead of print]

PMID:
30602164
5.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 11;:.

PMID:
30584090
6.

Low proliferative potential of adipose-derived stromal cells associates with hypertrophy and inflammation in subcutaneous and omental adipose tissue of patients with type 2 diabetes mellitus.

Stafeev I, Podkuychenko N, Michurina S, Sklyanik I, Panevina A, Shestakova E, Yah'yaev K, Fedenko V, Ratner E, Vorotnikov A, Menshikov M, Yashkov Y, Parfyonova Y, Shestakova M.

J Diabetes Complications. 2019 Feb;33(2):148-159. doi: 10.1016/j.jdiacomp.2018.10.011. Epub 2018 Nov 4.

PMID:
30482492
7.

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES.

PLoS One. 2018 Nov 16;13(11):e0207399. doi: 10.1371/journal.pone.0207399. eCollection 2018.

8.

Low-Grade Appendiceal Mucinous Neoplasm Diagnosed during Exploratory Laparoscopy for a Presumed Pelvic Mass.

Hosier H, Ratner E, Menderes G.

J Minim Invasive Gynecol. 2018 Nov 8. pii: S1553-4650(18)31345-1. doi: 10.1016/j.jmig.2018.11.001. [Epub ahead of print]

PMID:
30414997
9.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.

Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.

J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25.

PMID:
30255380
10.

Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy.

Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S.

Support Care Cancer. 2019 Apr;27(4):1425-1433. doi: 10.1007/s00520-018-4441-5. Epub 2018 Sep 5.

PMID:
30187220
11.

Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.

Lin ZP, Zhu YL, Ratner ES.

Front Oncol. 2018 Aug 8;8:303. doi: 10.3389/fonc.2018.00303. eCollection 2018. Review.

12.

Modulation of the Inflammatory Status of Macrophages and Their Paracrine Effect on the Sensitivity of Adipocytes to Insulin with Sirtuin and PPARγ Receptor Activators.

Stafeev YS, Michurina SS, Zubkova ES, Beloglazova IB, Ratner EI, Parfenova EV, Men'shikov MY.

Bull Exp Biol Med. 2018 Aug;165(4):429-433. doi: 10.1007/s10517-018-4186-7. Epub 2018 Aug 18.

PMID:
30121911
13.

C-Kit Cardiac Progenitor Cell Based Cell Sheet Improves Vascularization and Attenuates Cardiac Remodeling following Myocardial Infarction in Rats.

Dergilev K, Tsokolaeva Z, Makarevich P, Beloglazova I, Zubkova E, Boldyreva M, Ratner E, Dyikanov D, Menshikov M, Ovchinnikov A, Ageev F, Parfyonova Y.

Biomed Res Int. 2018 Jun 25;2018:3536854. doi: 10.1155/2018/3536854. eCollection 2018.

14.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.

PMID:
29941483
15.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2018 Jan 1:1933719118778801. doi: 10.1177/1933719118778801. [Epub ahead of print]

PMID:
29843577
16.

Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium Pain Task Force White Paper.

Tick H, Nielsen A, Pelletier KR, Bonakdar R, Simmons S, Glick R, Ratner E, Lemmon RL, Wayne P, Zador V; Pain Task Force of the Academic Consortium for Integrative Medicine and Health.

Explore (NY). 2018 May - Jun;14(3):177-211. doi: 10.1016/j.explore.2018.02.001. Epub 2018 Mar 1.

17.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.

J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.

PMID:
29584549
18.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.

PMID:
29572027
19.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
20.

Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.

Wong S, Ratner E, Buza N.

Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.

PMID:
29484698

Supplemental Content

Loading ...
Support Center